Historically, non-small cell lung cancer (NSCLC) treatment involved three modalities: surgery, radiation therapy and chemotherapy. In the last two decades, the treatment landscape of NSCLC has greatly ...
News-Medical.Net on MSN
Study finds a new protein target against KRAS-driven non-small cell lung cancer
In a study published in The Journal of Clinical Investigation, University of Michigan researchers found a new protein target ...
The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...
NSCLC treatment is stage-dependent, involving surgery, chemotherapy, radiation, immunotherapy, and targeted therapy based on tumor genetics. Molecular profiling is essential for personalized treatment ...
Hernexeos (zongertinib) received FDA accelerated approval for unresectable or metastatic non-squamous NSCLC with HER2 TKD mutations after prior treatment. The Beamion LUNG-1 trial showed a 75% ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
“Lung cancer, though common and serious, still has many misconceptions,” says Ian Bostock, MD, a thoracic surgeon at Miami Cancer Institute in Florida. “Clearing these myths helps patients and ...
Ask a clinical question and tap into Healio AI's knowledge base. Lung cancer in general, and non-small cell lung cancer (NSCLC) in particular, is often asymptomatic in the early stages of the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback